✦ LIBER ✦

Phase II protocol for the evaluation of new treatments in patients with advanced gastric carcinoma: results of ECOG 5282

✍ Scribed by Y Novik; LM Ryan; DG Haller; R Asbury; JP Dutcher; A Schutt

Publisher: Springer US
Year: 1999
Tongue: English
Weight: 432 KB
Volume: 16
Category: Article
ISSN: 1357-0560
DOI: 10.1007/bf02785872

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II study of Temodal in the treatme

Phase II study of Temodal in the treatment of patients with advanced nasopharyngeal carcinoma

✍ Anthony T. C. Chan; Thomas W. T. Leung; Wing H. Kwan; Tony S. K. Mok; Winnie Yeo 📂 Article 📅 1998 🏛 Springer 🌐 English ⚖ 246 KB

CPT-11 plus cisplatin in patients with a

CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma : Results of a Phase II study

✍ Jaffer A. Ajani; Jackie Baker; Peter W. T. Pisters; Linus Ho; Paul F. Mansfield; 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 138 KB

Phase II study of gemcitabine and cispla

Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma

✍ Philip A. Philip; Mark M. Zalupski; V. K. Vaitkevicius; Patricia Arlauskas; Ruth 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 101 KB 👁 2 views

Phase II clinical trial of SKI-2053R, a

Phase II clinical trial of SKI-2053R, a new platinum analog, in the treatment of patients with advanced gastric adenocarcinoma

✍ Noe K. Kim; Seock-Ah Im; Dong-Wan Kim; Moon H. Lee; Chul W. Jung; Eun K. Cho; Jo 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB 👁 2 views

BACKGROUND. SKI-2053R (SK Chemicals, Kyungki-Do, South Korea) is a new platinum derivative with antitumor activity against various cell lines, including cisplatin-resistant tumor cell lines. Preclinical studies have suggested that it is less nephrotoxic than cisplatin. This study evaluated the effic

A phase III evaluation of a somatostatin

A phase III evaluation of a somatostatin analogue (octreotide) in the treatment of patients with asymptomatic advanced colon carcinoma

✍ Richard M. Goldberg; Charles G. Moertel; Harry S. Wieand; James E. Krook; Allan 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 499 KB 👁 3 views

A phase III evaluation of a somatostatin

A phase III evaluation of a somatostatin analogue (octreotide) in the treatment of patients with asymptomatic advanced colon carcinoma

✍ David L. Morris 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB 👁 3 views

I of a Somatostatin Analogue (Octreotide) in the Treatment of Patients with Asymptomatic Advanced Colon Cancer."' The disappointing results of this study contrast with recently reported cellular kinetic data for rectal cancer treatment with somatostatin. It should be noted that the dosage used in o